BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA
BeOne Medicines (ONC) will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in line with recent fixed-duration studies in fitter, healthier patient populations. Additionally, 11 patients in Arm D were able to discontinue treatment early due to meeting uMRD-guided stopping criteria, and 9 patients remain in ongoing clinical remission with sustained uMRD, allowing them to remain treatment-free. In patients without del(17p) and TP53 mutations, 43% achieved uMRD by cycle 16 and 60% by cycle 28. These data were published today in the Journal of Clinical Oncology.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Menopause Drug Reduces Breast Cancer Growth In Clinical Trial
A drug used to relieve the debilitating symptoms of menopause may also be reducing the risk of invasive breast cancer, a new clinical trial by Northwestern University suggests. Almost 60,000 women a year are diagnosed with a contained form of breast cancer that can indicate a higher risk of developing invasive tumors later in life. The non-invasive cancer is typically detected during routine mammograms, accounts for up to 25 percent of all breast cancer diagnoses, and has a 98 percent recovery rate after 10 years when removed by surgery. However, to increase their chance of remaining cancer-free many patients also undergo treatments like radiation and hormone therapy following surgery. These treatments often have debilitating side effects. The phase two clinical trial recruited 141 postmenopausal women who have a form of contained breast cancer called ductal carcinoma tumors. Half of them were given a medication for managing symptoms of menopause called Duavee; others were administered a placebo for the month between diagnosis and breast cancer surgery. Duavee is composed of estrogen hormones and bazedoxifene – a molecule that either promotes or dampens the use of estrogens in the body, depending on the type of tissue it is in. This estrogen receptor modifier is also used to help treat osteoporosis. Those who took the drug had notably less cell growth in their breast tissue by their surgery date. There was also "no impact on quality of life compared to placebo." "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," says Northwestern University surgeon Swati Kulkarni. Significantly, trial participants taking Duavee did not experience the intolerable side effects associated with other cancer drugs. Rather, it tends to increase the quality of life in people already struggling with menopause. While larger studies are still needed to confirm Duavee's ability to prevent breast cancer, Kulkarni and team suggest that, for now, those with elevated risk for breast cancer as well as menopausal symptoms would most likely benefit from Duavee. Especially given women with prior cancer lesions can't resort to hormone treatments to ease their menopause symptoms because they can increase the risk of breast cancer returning. "These results support consideration that [Duavee] is a safe option to manage menopausal symptoms for women concerned about their risk of developing breast cancer, and provide supportive evidence that [Duavee] may reduce the risk of developing invasive breast cancer," the researchers conclude in their conference abstract. The trial results have yet to be published but were presented at the American Society of Clinical Oncology's latest annual meeting. Bowel Cancer in Young People Is Rising – Here's How to Reduce Your Risk Why Do Some People Need Less Sleep? The Answer Lies in Our Genes. Regular Exercise Reduces Death From Colon Cancer by 37%, Study Finds
Yahoo
18 hours ago
- Yahoo
OceanaGold Reports Voting Results from its 2025 Annual General and Special Meeting
VANCOUVER, BC, June 4, 2025 /CNW/ - OceanaGold Corporation (TSX: OGC), (TSX: OTCQX) (TSX: OCANF) ("OceanaGold" or the "Company") is pleased to report the voting results from the Company's 2025 Annual General and Special Meeting of Shareholders (the "Annual Meeting") held today. A total of 538,458,035 common shares were voted at the meeting, representing 77.12% of the votes attached to all outstanding common shares. Shareholders voted in favour of each of the items of business at the Annual Meeting as follows: Election of Directors Resolutions electing each of the director nominees listed in OceanaGold's Management Information Circular dated April 23, 2025 as directors of the Company were passed by ordinary resolution. Detailed results of the vote for each director are set out in the table below: Directors Votes For % Votes Withheld / Abstain % Paul Benson 393,936,966 79.79 99,784,006 20.21 Ian M. Reid 488,729,245 98.99 4,991,727 1.01 Craig J. Nelsen 491,026,458 99.45 2,694,514 0.55 Sandra M. Dodds 482,121,086 97.65 11,599,886 2.35 Alan N. Pangbourne 490,403,457 99.33 3,317,515 0.67 Linda M. Broughton 491,015,000 99.45 2,705,972 0.55 Stefanie E. Loader 493,423,819 99.94 297,153 0.06 Gerard M. Bond 493,434,771 99.94 286,201 0.06 Share Consolidation A special resolution approving the consolidation of all issued and outstanding common shares of the Company on a consolidation ratio of up to three (3) pre-consolidation common shares for one (1) post-consolidation common share (the "Consolidation") was passed. Votes For % Votes Against % 536,892,725 99.71 1,565,307 0.29 The Company is exploring the benefits of a dual listing of its common shares on a major U.S. exchange, including the New York Stock Exchange, for a potential listing in the first half of 2026. The Company believes a U.S. listing could lead to increased interest by a wider audience of potential investors and result in increased marketability and trading liquidity. The principal reason for the Consolidation is to raise the per share trading price of the common shares in order to better comply with minimum trading price requirements of such exchanges. Subject to approval by the Toronto Stock Exchange, OceanaGold expects the Consolidation to be effective on or around June 23, 2025, and intends to issue a detailed press release to provide a further update and final details on the Consolidation. Appointment of Auditor A resolution appointing PricewaterhouseCoopers LLP (PWC Canada) as the auditor of the Company for the ensuing year and authorizing the board of the Company to fix their remuneration was passed. Votes For % Votes Withheld / Abstain % 508,912,534 94.51 29,545,500 5.49 Advisory Vote on Executive Compensation A non-binding resolution on the Company's approach to executive compensation was passed. Votes For % Votes Against % 480,384,783 97.30 13,336,189 2.70 Virtual-Only Meetings A resolution approving the Company to hold the 2026 Annual General Meeting of Shareholders exclusively in a virtual-only format was passed. Votes For % Votes Against % 325,303,717 65.89 168,417,253 34.11 Amendments to the Company's Articles A special resolution approving amendments to the Company's articles was passed. Votes For % Votes Against % 491,746,774 99.60 1,974,197 0.40 About OceanaGold OceanaGold is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the Haile Gold Mine in the United States of America; Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. Cautionary Statement for Public Release This press release contains certain "forward-looking statements" and "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws which may include, but is not limited to, statements with respect to the Company being listed on a major U.S. exchange, including such dual listing leading to increased interest by a wider audience of potential investors, increased marketability and trading liquidity and the expected timing for such listing, and the anticipated timing and effects of the completion of the Consolidation. Forward-looking statements and information relate to future performance and reflect the Company's expectations regarding the generation of Free Cash Flow, execution of business strategy, future growth, future production, estimated costs, results of operations, business prospects and opportunities of OceanaGold and its related subsidiaries. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those expressed in the forward-looking statements. They include, among others, those risk factors identified in the Company's most recent Annual Information Form prepared and filed with securities regulators which is available on SEDAR+ at under the Company's name and on the Company's website. There are no assurances the Company can fulfil forward-looking statements. Such forward-looking statements are only predictions based on current information available to management as of the date that such predictions are made; actual events or results may differ materially as a result of risks facing the Company, some of which are beyond the Company's control. Although the Company believes that any forward-looking statements contained in this press release is based on reasonable assumptions, readers cannot be assured that actual outcomes or results will be consistent with such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information, whether as a result of new information, events or otherwise, except as required by applicable securities laws. View original content to download multimedia: SOURCE OceanaGold Corporation View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19 hours ago
- Yahoo
OceanaGold Reports Voting Results from its 2025 Annual General and Special Meeting
VANCOUVER, BC, June 4, 2025 /PRNewswire/ - OceanaGold Corporation (TSX: OGC), (TSX: OTCQX) (TSX: OCANF) ("OceanaGold" or the "Company") is pleased to report the voting results from the Company's 2025 Annual General and Special Meeting of Shareholders (the "Annual Meeting") held today. A total of 538,458,035 common shares were voted at the meeting, representing 77.12% of the votes attached to all outstanding common shares. Shareholders voted in favour of each of the items of business at the Annual Meeting as follows: Election of Directors Resolutions electing each of the director nominees listed in OceanaGold's Management Information Circular dated April 23, 2025 as directors of the Company were passed by ordinary resolution. Detailed results of the vote for each director are set out in the table below: Directors Votes For % Votes Withheld / Abstain % Paul Benson 393,936,966 79.79 99,784,006 20.21 Ian M. Reid 488,729,245 98.99 4,991,727 1.01 Craig J. Nelsen 491,026,458 99.45 2,694,514 0.55 Sandra M. Dodds 482,121,086 97.65 11,599,886 2.35 Alan N. Pangbourne 490,403,457 99.33 3,317,515 0.67 Linda M. Broughton 491,015,000 99.45 2,705,972 0.55 Stefanie E. Loader 493,423,819 99.94 297,153 0.06 Gerard M. Bond 493,434,771 99.94 286,201 0.06 Share Consolidation A special resolution approving the consolidation of all issued and outstanding common shares of the Company on a consolidation ratio of up to three (3) pre-consolidation common shares for one (1) post-consolidation common share (the "Consolidation") was passed. Votes For % Votes Against % 536,892,725 99.71 1,565,307 0.29 The Company is exploring the benefits of a dual listing of its common shares on a major U.S. exchange, including the New York Stock Exchange, for a potential listing in the first half of 2026. The Company believes a U.S. listing could lead to increased interest by a wider audience of potential investors and result in increased marketability and trading liquidity. The principal reason for the Consolidation is to raise the per share trading price of the common shares in order to better comply with minimum trading price requirements of such exchanges. Subject to approval by the Toronto Stock Exchange, OceanaGold expects the Consolidation to be effective on or around June 23, 2025, and intends to issue a detailed press release to provide a further update and final details on the Consolidation. Appointment of Auditor A resolution appointing PricewaterhouseCoopers LLP (PWC Canada) as the auditor of the Company for the ensuing year and authorizing the board of the Company to fix their remuneration was passed. Votes For % Votes Withheld / Abstain % 508,912,534 94.51 29,545,500 5.49 Advisory Vote on Executive Compensation A non-binding resolution on the Company's approach to executive compensation was passed. Votes For % Votes Against % 480,384,783 97.30 13,336,189 2.70 Virtual-Only Meetings A resolution approving the Company to hold the 2026 Annual General Meeting of Shareholders exclusively in a virtual-only format was passed. Votes For % Votes Against % 325,303,717 65.89 168,417,253 34.11 Amendments to the Company's Articles A special resolution approving amendments to the Company's articles was passed. Votes For % Votes Against % 491,746,774 99.60 1,974,197 0.40 About OceanaGold OceanaGold is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the Haile Gold Mine in the United States of America; Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. Cautionary Statement for Public Release This press release contains certain "forward-looking statements" and "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws which may include, but is not limited to, statements with respect to the Company being listed on a major U.S. exchange, including such dual listing leading to increased interest by a wider audience of potential investors, increased marketability and trading liquidity and the expected timing for such listing, and the anticipated timing and effects of the completion of the Consolidation. Forward-looking statements and information relate to future performance and reflect the Company's expectations regarding the generation of Free Cash Flow, execution of business strategy, future growth, future production, estimated costs, results of operations, business prospects and opportunities of OceanaGold and its related subsidiaries. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those expressed in the forward-looking statements. They include, among others, those risk factors identified in the Company's most recent Annual Information Form prepared and filed with securities regulators which is available on SEDAR+ at under the Company's name and on the Company's website. There are no assurances the Company can fulfil forward-looking statements. Such forward-looking statements are only predictions based on current information available to management as of the date that such predictions are made; actual events or results may differ materially as a result of risks facing the Company, some of which are beyond the Company's control. Although the Company believes that any forward-looking statements contained in this press release is based on reasonable assumptions, readers cannot be assured that actual outcomes or results will be consistent with such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information, whether as a result of new information, events or otherwise, except as required by applicable securities laws. View original content to download multimedia: SOURCE OceanaGold Corporation
